Symbols / STTK
STTK Chart
About
Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company's lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involved in the advancement of its lead TRIM7 inhibitors through preclinical development as future internal pipeline candidates in oncology. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 270.84M |
| Enterprise Value | 187.34M | Income | -54.90M | Sales | 1.00M |
| Book/sh | 1.48 | Cash/sh | 1.36 | Dividend Yield | — |
| Payout | 0.00% | Employees | 44 | IPO | — |
| P/E | — | Forward P/E | -8.36 | PEG | — |
| P/S | 270.84 | P/B | 2.90 | P/C | — |
| EV/EBITDA | -3.48 | EV/Sales | 187.34 | Quick Ratio | 16.14 |
| Current Ratio | 17.00 | Debt/Eq | 2.82 | LT Debt/Eq | — |
| EPS (ttm) | -0.99 | EPS next Y | -0.51 | EPS Growth | — |
| Revenue Growth | -66.60% | Earnings | 2026-03-26 | ROA | -33.93% |
| ROE | -57.84% | ROIC | — | Gross Margin | 21.70% |
| Oper. Margin | -10.72% | Profit Margin | 0.00% | Shs Outstand | 63.28M |
| Shs Float | 37.94M | Short Float | 4.72% | Short Ratio | 2.54 |
| Short Interest | — | 52W High | 4.89 | 52W Low | 0.69 |
| Beta | 1.56 | Avg Volume | 560.48K | Volume | 303.13K |
| Target Price | $7.25 | Recom | Buy | Prev Close | $4.23 |
| Price | $4.28 | Change | 1.18% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.25
Mean price target
2. Current target
$4.28
Latest analyst target
3. DCF / Fair value
$-7.98
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.28
Low
$4.00
High
$15.00
Mean
$7.25
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-28 | init | Piper Sandler | — → Overweight | $15 |
| 2026-01-06 | main | Citigroup | Neutral → Neutral | $4 |
| 2025-12-01 | up | HC Wainwright & Co. | Neutral → Buy | $6 |
| 2025-09-08 | init | Wedbush | — → Outperform | $4 |
| 2025-08-14 | main | Leerink Partners | Outperform → Outperform | $2 |
| 2025-08-14 | reit | Needham | Hold → Hold | — |
| 2025-03-27 | reit | Needham | Hold → Hold | — |
| 2025-03-27 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-17 | init | Leerink Partners | — → Outperform | $4 |
| 2024-11-15 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-11-14 | reit | Needham | — → Hold | — |
| 2024-10-02 | down | Citigroup | Buy → Neutral | $2 |
| 2024-10-02 | down | Needham | Buy → Hold | $8 |
| 2024-10-01 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2024-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-08-15 | main | Citigroup | Buy → Buy | $8 |
| 2024-08-02 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-08-02 | reit | Needham | Buy → Buy | $8 |
| 2024-06-20 | main | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-06-17 | main | Citigroup | Buy → Buy | $9 |
- $STTK stock is up 9% today. Here's what we see in our data. - Quiver Quantitative Wed, 28 Jan 2026 08
- What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now? - Yahoo Finance Wed, 08 Oct 2025 07
- Shattuck Labs Sets Earlier Date for 2026 Annual Meeting - The Globe and Mail Fri, 06 Feb 2026 08
- Shattuck Labs (STTK) Price Target Increased by 55.36% to 7.40 - Nasdaq Wed, 04 Feb 2026 08
- Shattuck Labs (NASDAQ: STTK) to Join Piper Sandler and Evercore December Events - Stock Titan hu, 20 Nov 2025 08
- Shattuck earns new Overweight at Piper Sandler ahead of upcoming catalysts - Seeking Alpha Wed, 28 Jan 2026 08
- Shattuck Labs Stock Jump Looks Great, But How Secure Is That Gain? - Trefis Sun, 21 Dec 2025 08
- Shattuck Labs, Inc.'s (NASDAQ:STTK) biggest owners are retail investors who got richer after stock soared 10% last week - simplywall.st ue, 30 Dec 2025 08
- Why Shattuck Labs Stock Soared in December - The Motley Fool Mon, 05 Jan 2026 08
- Piper Sandler Initiates Coverage on STTK with Overweight Rating - GuruFocus Wed, 28 Jan 2026 17
- STTK Stock Surge: Time to Strike? - StocksToTrade ue, 05 Aug 2025 07
- Insider Purchase: Director at $STTK Buys 5,255,106 Shares | STTK Stock News - Quiver Quantitative Wed, 03 Sep 2025 07
- Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Mon, 08 Sep 2025 07
- Shattuck Labs Just Shocked Wall Street: Is STTK the Next Sleeper Biotech Rocket or Total Trap? - AD HOC NEWS Mon, 16 Feb 2026 07
- Shattuck Labs: "Hold" On Oncology Exit And Competitive TL1A/DR3 Pathway Pivot (STTK) - Seeking Alpha Fri, 16 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 25610 | 22222 | — | Stock Award(Grant) at price 0.87 per share. | SCHREIBER TAYLOR M.D., PH.D. | Chief Executive Officer | — | 2025-08-25 00:00:00 | D |
| 1 | 6306127 | 5471826 | — | Purchase at price 0.87 per share. | ORBIMED ADVISORS, L.L.C. | Unknown | — | 2025-08-25 00:00:00 | I |
| 2 | 6306127 | 5471826 | — | Purchase at price 0.87 per share. | ASHIYA MONA | Director | — | 2025-08-25 00:00:00 | I |
| 3 | 64027 | 55556 | — | Stock Award(Grant) at price 0.87 per share. | NEILL ANDREW R. | Chief Financial Officer | — | 2025-08-25 00:00:00 | D |
| 4 | 5122 | 4444 | — | Stock Award(Grant) at price 0.87 per share. | SHUKLA ABHINAV A. PH.D. | Chief Technology Officer | — | 2025-08-25 00:00:00 | D |
| 5 | 12805 | 11111 | — | Stock Award(Grant) at price 0.87 per share. | STOUT STEPHEN | General Counsel | — | 2025-08-25 00:00:00 | D |
| 6 | 128054 | 111112 | — | Stock Award(Grant) at price 0.87 per share. | SIEGALL CLAY B | Director | — | 2025-08-25 00:00:00 | D |
| 7 | 133371 | 166714 | — | Purchase at price 1.25 per share. | REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-04 00:00:00 | I |
| 8 | 133371 | 166714 | — | Sale at price 1.25 per share. | REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-04 00:00:00 | I |
| 9 | 36500 | 44220 | — | Purchase at price 1.21 per share. | SCHREIBER TAYLOR M.D., PH.D. | Chief Executive Officer | — | 2024-10-07 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -76.74M | -87.92M | -100.26M | -43.89M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -75.41M | -87.30M | -101.94M | -44.97M |
| ReconciledDepreciation | 3.83M | 4.04M | 3.07M | 1.38M |
| EBITDA | -76.74M | -87.92M | -100.26M | -43.89M |
| EBIT | -80.57M | -91.96M | -103.33M | -45.27M |
| NetInterestIncome | 5.17M | 4.67M | 1.59M | 625.00K |
| InterestIncome | 5.17M | 4.67M | 1.59M | 625.00K |
| NormalizedIncome | -75.41M | -87.30M | -101.94M | -44.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -75.41M | -87.30M | -101.94M | -44.97M |
| TotalExpenses | 86.29M | 93.61M | 103.98M | 75.29M |
| TotalOperatingIncomeAsReported | -80.57M | -91.96M | -103.33M | -45.27M |
| DilutedAverageShares | 50.76M | 42.60M | 42.38M | 42.03M |
| BasicAverageShares | 50.76M | 42.60M | 42.38M | 42.03M |
| DilutedEPS | -1.49 | -2.05 | -2.41 | -1.07 |
| BasicEPS | -1.49 | -2.05 | -2.41 | -1.07 |
| DilutedNIAvailtoComStockholders | -75.41M | -87.30M | -101.94M | -44.97M |
| NetIncomeCommonStockholders | -75.41M | -87.30M | -101.94M | -44.97M |
| NetIncome | -75.41M | -87.30M | -101.94M | -44.97M |
| NetIncomeIncludingNoncontrollingInterests | -75.41M | -87.30M | -101.94M | -44.97M |
| NetIncomeContinuousOperations | -75.41M | -87.30M | -101.94M | -44.97M |
| PretaxIncome | -75.41M | -87.30M | -101.94M | -44.97M |
| OtherIncomeExpense | -17.00K | -10.00K | -208.00K | -330.00K |
| OtherNonOperatingIncomeExpenses | -17.00K | -10.00K | -208.00K | -330.00K |
| NetNonOperatingInterestIncomeExpense | 5.17M | 4.67M | 1.59M | 625.00K |
| InterestIncomeNonOperating | 5.17M | 4.67M | 1.59M | 625.00K |
| OperatingIncome | -80.57M | -91.96M | -103.33M | -45.27M |
| OperatingExpense | 86.29M | 93.61M | 103.98M | 75.29M |
| ResearchAndDevelopment | 67.21M | 74.31M | 82.90M | 56.56M |
| SellingGeneralAndAdministration | 19.08M | 19.30M | 21.08M | 18.72M |
| GeneralAndAdministrativeExpense | 19.08M | 19.30M | 21.08M | 18.72M |
| OtherGandA | 19.08M | 19.30M | 21.08M | 18.72M |
| TotalRevenue | 5.72M | 1.66M | 652.00K | 30.02M |
| OperatingRevenue | 5.72M | 1.66M | 652.00K | 30.02M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 47.71M | 47.26M | 42.39M | 42.34M |
| ShareIssued | 47.71M | 47.26M | 42.39M | 42.34M |
| TotalDebt | 3.41M | 4.20M | 4.90M | 0.00 |
| TangibleBookValue | 79.63M | 144.71M | 176.16M | 271.79M |
| InvestedCapital | 79.63M | 144.71M | 176.16M | 271.79M |
| WorkingCapital | 70.30M | 131.77M | 159.62M | 263.68M |
| NetTangibleAssets | 79.63M | 144.71M | 176.16M | 271.79M |
| CapitalLeaseObligations | 3.41M | 4.20M | 4.90M | 0.00 |
| CommonStockEquity | 79.63M | 144.71M | 176.16M | 271.79M |
| TotalCapitalization | 79.63M | 144.71M | 176.16M | 271.79M |
| TotalEquityGrossMinorityInterest | 79.63M | 144.71M | 176.16M | 271.79M |
| StockholdersEquity | 79.63M | 144.71M | 176.16M | 271.79M |
| GainsLossesNotAffectingRetainedEarnings | 2.00K | 4.00K | -877.00K | -560.00K |
| OtherEquityAdjustments | 2.00K | 4.00K | -877.00K | |
| RetainedEarnings | -381.72M | -306.31M | -219.01M | -117.07M |
| AdditionalPaidInCapital | 461.34M | 451.01M | 396.04M | 389.41M |
| CapitalStock | 5.00K | 5.00K | 5.00K | 5.00K |
| CommonStock | 5.00K | 5.00K | 5.00K | 5.00K |
| TotalLiabilitiesNetMinorityInterest | 11.42M | 14.86M | 29.17M | 26.80M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.51M | 3.41M | 4.20M | 2.21M |
| NonCurrentDeferredLiabilities | 0.00 | 2.21M | ||
| NonCurrentDeferredRevenue | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 2.51M | 3.41M | 4.20M | 0.00 |
| LongTermCapitalLeaseObligation | 2.51M | 3.41M | 4.20M | 0.00 |
| CurrentLiabilities | 8.92M | 11.45M | 24.96M | 24.59M |
| OtherCurrentLiabilities | 410.00K | 1.04M | 1.87M | 1.00M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 900.00K | 796.00K | 701.00K | |
| CurrentCapitalLeaseObligation | 900.00K | 796.00K | 701.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.29M | 3.79M | 3.97M | 3.32M |
| PayablesAndAccruedExpenses | 5.32M | 5.82M | 18.43M | 20.27M |
| CurrentAccruedExpenses | 2.90M | 4.24M | 11.26M | 10.25M |
| Payables | 2.42M | 1.59M | 7.17M | 10.01M |
| AccountsPayable | 2.42M | 1.59M | 7.17M | 10.01M |
| TotalAssets | 91.05M | 159.56M | 205.32M | 298.58M |
| TotalNonCurrentAssets | 11.83M | 16.34M | 20.74M | 10.32M |
| OtherNonCurrentAssets | 2.02M | 2.54M | 3.07M | 381.00K |
| NetPPE | 9.81M | 13.80M | 17.67M | 9.94M |
| AccumulatedDepreciation | -13.22M | -9.51M | -5.71M | -2.78M |
| GrossPPE | 23.03M | 23.31M | 23.38M | 12.72M |
| Leases | 7.10M | 7.10M | 7.09M | 3.71M |
| ConstructionInProgress | 0.00 | 100.00K | 104.00K | 2.52M |
| OtherProperties | 15.29M | 15.47M | 15.55M | 5.82M |
| MachineryFurnitureEquipment | 644.00K | 644.00K | 643.00K | 665.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 79.22M | 143.22M | 184.58M | 288.27M |
| OtherCurrentAssets | 6.23M | 12.60M | 23.30M | 19.46M |
| PrepaidAssets | 19.46M | |||
| CashCashEquivalentsAndShortTermInvestments | 72.99M | 130.62M | 161.28M | 268.80M |
| OtherShortTermInvestments | 15.60M | 5.00M | 113.90M | 176.54M |
| CashAndCashEquivalents | 57.39M | 125.63M | 47.38M | 92.27M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -60.57M | -81.64M | -106.11M | -65.04M |
| RepurchaseOfCapitalStock | -17.00K | |||
| IssuanceOfCapitalStock | 48.17M | 0.00 | 0.00 | |
| CapitalExpenditure | -59.00K | -407.00K | -11.61M | -7.93M |
| EndCashPosition | 57.39M | 125.63M | 47.38M | 92.27M |
| BeginningCashPosition | 125.63M | 47.38M | 92.27M | 157.90M |
| ChangesInCash | -68.24M | 78.25M | -44.89M | -65.63M |
| FinancingCashFlow | 787.00K | 48.62M | 171.00K | 1.93M |
| CashFlowFromContinuingFinancingActivities | 787.00K | 48.62M | 171.00K | 1.93M |
| NetOtherFinancingCharges | -451.00K | -53.00K | ||
| ProceedsFromStockOptionExercised | 1.25M | 499.00K | 171.00K | 1.93M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | -17.00K | 48.17M | 0.00 | 0.00 |
| CommonStockPayments | -17.00K | |||
| CommonStockIssuance | 48.17M | 0.00 | 0.00 | |
| InvestingCashFlow | -8.51M | 110.86M | 49.44M | -10.44M |
| CashFlowFromContinuingInvestingActivities | -8.51M | 110.86M | 49.44M | -10.44M |
| NetInvestmentPurchaseAndSale | -8.45M | 111.27M | 60.95M | -2.52M |
| SaleOfInvestment | 85.10M | 191.00M | 193.32M | 201.57M |
| PurchaseOfInvestment | -93.55M | -79.73M | -132.38M | -204.09M |
| NetPPEPurchaseAndSale | -59.00K | -407.00K | -11.51M | -7.93M |
| SaleOfPPE | 0.00 | 104.00K | 0.00 | |
| PurchaseOfPPE | -59.00K | -407.00K | -11.61M | -7.93M |
| OperatingCashFlow | -60.52M | -81.23M | -94.50M | -57.12M |
| CashFlowFromContinuingOperatingActivities | -60.52M | -81.23M | -94.50M | -57.12M |
| ChangeInWorkingCapital | 3.02M | -4.09M | -4.46M | -22.02M |
| ChangeInOtherWorkingCapital | 343.00K | -27.51M | ||
| ChangeInOtherCurrentLiabilities | -900.00K | -796.00K | -702.00K | 0.00 |
| ChangeInOtherCurrentAssets | 90.00K | 165.00K | -53.00K | -32.00K |
| ChangeInPayablesAndAccruedExpense | -2.54M | -13.92M | 133.00K | 14.79M |
| ChangeInAccruedExpense | -3.37M | -8.29M | 2.98M | 6.92M |
| ChangeInPayable | 832.00K | -5.63M | -2.84M | 7.87M |
| ChangeInAccountPayable | 832.00K | -5.63M | -2.84M | 7.87M |
| ChangeInPrepaidAssets | 6.37M | 10.46M | -3.84M | -9.27M |
| OtherNonCashItems | 428.00K | 364.00K | 302.00K | 1.52M |
| StockBasedCompensation | 9.55M | 6.94M | 6.46M | 5.47M |
| AmortizationOfSecurities | -2.15M | -1.48M | 1.37M | 3.04M |
| DepreciationAmortizationDepletion | 3.83M | 4.04M | 3.07M | 1.38M |
| DepreciationAndAmortization | 3.83M | 4.04M | 3.07M | 1.38M |
| Depreciation | 3.83M | 4.04M | 3.07M | 1.38M |
| OperatingGainsLosses | 222.00K | 303.00K | 704.00K | |
| NetIncomeFromContinuingOperations | -75.41M | -87.30M | -101.94M | -44.97M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for STTK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|